FDA Advisers Question Efficacy of Roche’s Polivy in First Line LBCL

FDA advisers raised concerns regarding the efficacy and risk-benefit profile of Genentech’s Polivy as a first-line treatment for large B-cell lymphoma ahead of a March 9 advisory committee meeting.